Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Benzinga

2021-08-19

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.
Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).
Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).
Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).
There were no safety issues or venous ulcer recurrences.
The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.
Related: FDA Breakthrough Designation For Its Venous Insufficiency Device.
Price Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.

See more from Benzinga

Click here for options trades from Benzinga
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
NLS Pharma Stock Gains After Issuance Of Mazindol Patent

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2160250793"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2160250793\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2160250793?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W1VU5NXoeOklS4J17UGuUA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Bih0obOqAiTJL3YNmgwYhg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d","is_english":true,"pubTime":"2021-08-19 23:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2160250793","market":"us","top_or_hot":-1,"title":"Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/VRSnnXWuZ5LiJ.XdtF0LPA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Hancock Jaffe Laboratories Inc</strong> (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.</li>\n<li>Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.</li>\n<li>The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).</li>\n<li>Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).</li>\n<li>Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).</li>\n<li>There were no safety issues or venous ulcer recurrences.</li>\n<li>The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.</li>\n<li><em>Related: </em><em>FDA Breakthrough Designation For Its Venous Insufficiency Device</em><em>.</em></li>\n<li><strong>Price Action:</strong> HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action</li>\n<li>NLS Pharma Stock Gains After Issuance Of Mazindol Patent</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-19 23:49</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/VRSnnXWuZ5LiJ.XdtF0LPA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Hancock Jaffe Laboratories Inc</strong> (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.</li>\n<li>Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.</li>\n<li>The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).</li>\n<li>Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).</li>\n<li>Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).</li>\n<li>There were no safety issues or venous ulcer recurrences.</li>\n<li>The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.</li>\n<li><em>Related: </em><em>FDA Breakthrough Designation For Its Venous Insufficiency Device</em><em>.</em></li>\n<li><strong>Price Action:</strong> HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action</li>\n<li>NLS Pharma Stock Gains After Issuance Of Mazindol Patent</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HBHC","symbol_name":"漢考克控股銀行","start_time":0,"source_url":"https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html","article_id":"2160250793","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W1VU5NXoeOklS4J17UGuUA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Bih0obOqAiTJL3YNmgwYhg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2160250793","pubTimestamp":1629388195,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HBHC":"汉考克控股银行"},"translate_title":"汉考克·贾菲强调静脉功能不全瓣膜的两年数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HBHC":1,"HJLI":0.9},"content_text":"Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.\nData will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.\nThe results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).\nDisease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).\nPain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).\nThere were no safety issues or venous ulcer recurrences.\nThe VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.\nRelated: FDA Breakthrough Designation For Its Venous Insufficiency Device.\nPrice Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nGalmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action\nNLS Pharma Stock Gains After Issuance Of Mazindol Patent\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}